Foghorn therapeutics to present preclinical data for fhd-286 at the 2022 aacr annual meeting

Cambridge, mass., april 01, 2022 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the company will have an oral and late-breaking poster presentation at the upcoming american association for cancer research (aacr) annual meeting, taking place april 8-13, 2022, in new orleans, louisiana. presentations include preclinical data supporting the clinical development of the novel baf inhibitor fhd-286 for the treatment of acute myeloid leukemia (aml), myelodysplastic syndromes (mds) and metastatic uveal melanoma (um).
FHTX Ratings Summary
FHTX Quant Ranking